Takeda

- Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payments - - NDI-034858 has potential best-in-class…

Takeda announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2)…

Takeda and Enel North America announced the signing of a long-term virtual power purchase agreement (VPPA) for the electricity delivered to the power…

Data Include Exploratory Analysis Showing LIVTENCITY Treated Patients With Post-Transplant Cytomegalovirus (CMV) Infections/Disease Had…

− Nuvaxovid Intramuscular Injection, containing Matrix-MTM adjuvant, is the first recombinant protein-based COVID-19 vaccine approved for use in Japan…

This new initiative, which will run from 2022 to 2026, will build on existing activities as part of the current Takeda-WFP partnership A new JPY…

Qstream, market leader in microlearning, announces it is recognised in the 2021 Fosway 9-Grid for Learning Systems. This new achievement reflects the…